Compugen to get $7.5M milestone as AstraZeneca begins dosing in cancer drug study

Nov. 16, 2022 8:31 AM ETCompugen Ltd. (CGEN)By: Ravikash, SA News Editor1 Comment

Business agreement

mediaphotos

  • Israel's Compugen (NASDAQ:CGENsaid it expects to receive a milestone payment of $7.5M from AstraZeneca as the British drugmaker dosed the first patient in its phase 2 trial of anti-tumor drug AZD2936.
  • The phase 2 study, dubbed ARTEMIDE, is evaluating AZD2936, a PD-1/TIGIT bispecific antibody derived from Compugen's clinical-stage anti-TIGIT antibody COM902.
  • "Like COM902, AZD2936 was engineered to reduce Fc effector functionality, with the potential to enhance anti-tumor activity," said Compugen President, and CEO Anat Cohen-Dayag.
  • The companies entered an agreement in 2018 granting AstraZeneca an exclusive license to use certain Compugen's monospecific antibodies.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.